Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1186210 | 0.97 | GSK3B (1.00) | GSK3B | |
| SCHEMBL8106175 | 0.97 | GSK3B (1.00) | GSK3B | |
| SCHEMBL1343323 | 0.92 | GSK3B (0.85) | GSK3B | |
| SCHEMBL1186105 | 0.91 | GSK3B (0.85) | GSK3B | |
| SCHEMBL8093215 | 0.91 | GSK3B (0.89) | GSK3B | |
| SCHEMBL1187995 | 0.90 | GSK3B (0.87) | GSK3B | |
| SCHEMBL17586407 | 0.90 | GSK3B (0.87) | GSK3B | |
| SCHEMBL1186113 | 0.90 | GSK3B (1.00) | GSK3B | |
| SCHEMBL1186244 | 0.90 | GSK3B (1.00) | GSK3B | |
| SCHEMBL8100177 | 0.89 | GSK3B (0.86) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2203459-B1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2016-03-16 | — | — | EP | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901112-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8476261-B2 | Spirocyclic aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009035684-A1 | SPIROCYCLIC AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034436-A1 | SPIROCYCLIC AMINOQUINOLNES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | GSK3B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.